Rho Kinases and Cardiac Remodeling

Toru Shimizu1, James K Liao

  • 1Section of Cardiology, Department of Medicine, University of Chicago.

Insights

Rho-associated coiled-coil containing kinases (ROCKs) contribute to cardiac fibrosis and hypertrophy. ROCK inhibition, using drugs like fasudil, shows therapeutic potential for treating hypertensive cardiac remodeling and heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Pharmacology

Background:

  • Hypertensive cardiac remodeling involves left ventricular hypertrophy and fibrosis, potentially leading to heart failure.
  • Rho-associated coiled-coil containing kinases (ROCKs), specifically ROCK1 and ROCK2, mediate RhoA signaling and are implicated in cardiovascular diseases.

Purpose of the Study:

  • To review the role of ROCKs in cardiac fibrosis and hypertrophy.
  • To discuss the therapeutic potential of ROCK inhibition for cardiac remodeling.

Main Methods:

  • Review of experimental studies on ROCKs in cardiac remodeling.
  • Analysis of data from ROCK inhibitor (e.g., fasudil) studies.
  • Examination of findings from genetically modified mouse models lacking ROCK isoforms.

Main Results:

  • ROCKs contribute to cardiac fibrosis and hypertrophy in pathological conditions.
  • ROCK inhibition demonstrates beneficial effects in experimental models of cardiac remodeling.
  • Genetic deletion of ROCK isoforms reduces myocardial fibrosis.

Conclusions:

  • ROCKs are key contributors to deleterious cardiac remodeling.
  • ROCKs represent promising therapeutic targets for cardiovascular diseases.
  • ROCK inhibition warrants further investigation for treating heart failure with preserved ejection fraction.

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
746